LIMN Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 45.43%, SMA50 36.32%, SMA200 -76.07%). The stock’s 14-day RSI is 66.77 (firm momentum), while the ATR of 0.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -96.82% below its high and over 98.18% above its low. Average 10-day trading volume of 10.89 million shares is significantly above the 3-month average of 1.40 million, indicating heightened recent market interest.

Liminatus Pharma, Inc. Class A Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.60. This means the shares are trading below this model’s fair value.

Liminatus Pharma, Inc. Class A Common Stock (NASDAQ:LIMN) closed at $1.07 USD, gaining $0.50 (87.36%) from the previous close of $0.57. The stock is currently mid-range between its 52-week high and low $0.54 and $33.66. With a market capitalization of about $28.96 million, Liminatus Pharma, Inc. Class A Common Stock is classified as a micro-cap and shows lower-than-market volatility (beta ~0.41). Key stats such as the average daily volume over the past year has been around 220.14 thousand shares, trading with heavier-than-usual volume. Headquartered in La Palma, CA, Liminatus Pharma, Inc. Class A Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Chris Kim, the company employs approximately 3 people and listed since May 01, 2025. Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies.

Liminatus Pharma, Inc. Class A Common Stock trades at a P/E ratio of -11.31, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -17.72 indicating negative book value, which may reflect financial stress. The P/FCF stands at -2.82, also above market averages.

Our AI price prediction model suggests that Liminatus Pharma, Inc. Class A Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -51.4%, with price expected at $0.52 by February 16, 2026, within a range of $0.43 to $0.61 3-Month Outlook: Projected fall of -95.33%, reaching $0.05 by May 01, 2026, with a range of $0.00 to $0.44. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by February 02, 2027, within a range of $0.00 to $0.56.

Liminatus Pharma, Inc. Class A Common Stock (NASDAQ:LIMN) shares are up 19.67% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Liminatus Pharma, Inc. Class A Common Stock trading at a premium to the broader market with a P/E of -11.31. Our AI forecast model points to short-term weakness (-51.4% over two weeks), a medium-term fall (-95.33% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.